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Abstract –  
Background: The European crisis lead to funding restrains in healthcare, already under pressure due to the ageing of the 
population and the increase of demands from innovation. Portugal is the paradigm of the European crisis since has both an 
economic and demographic crisis. 
The researchers aimed to evaluate the impact of economic restrains in Portugal for access and reimbursement of new 
oncological drugs. 
Methodology: A qualitative approach was used, supported by 27 formal, tape recorded, semi-structured interviews to 
representatives of the different healthcare stakeholders and policymakers.  The content analysis with semantic associations 
through co-occurrence analysis were done with the support of Tropes® software. 
Results: The results of the content analysis showed that economic restrains are leading to a policy of cost control with lower 
prices and reduced access to innovation; an excessive delay in the approval of new drugs; lack of transparency; serious 
limitations and inequity between hospitals. Contractual boundaries to national prescription was established and agreements 
with pharmaceuticals were made. Changes in the reimbursement process are being implemented with an increase of risk 
sharing mechanisms and implementation of a new system of health technological evaluation (SINATS). Treatment protocols 
are also being revised and public hospitals are trying to increase the number of clinical trials but there is still much 
bureaucracy. In this qualitative approach, the following factors with impact on survival were identified: Innovation and 
technological development, government funding, the price of drugs and type of oncological diseases. 
Conclusions: The economic crisis is leading to a very serious problem of inequity. However, it is also an opportunity for a 
structural reform. In Portugal, an attempt of reform is being made with the implementation of SINATS since it is important to 
distinguish molecules that effectively bring added value. In order to consider the strategic vision in which the patient is the 
center of all efforts, the process of reimbursement approval for new medicines should be faster, more transparent and 
interdisciplinary. Moreover, the decisions must be done triangulating evidence based medicine, economics, health policy and 
ethical and legal issues. For National Health Service sustainability, efficiency and efficacy, clinical and economic 
reassessments must be done after market introduction of new medicines, with subsequent renegotiations. 
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I. INTRODUCTION 
 
The healthcare cost of cancer care to European Union 
healthcare systems in 2009 was €51·0 billion, and 
accounted for 4% of total healthcare spending (1).  
The regulatory agencies (such as the EMEA and 
FDA), governments, non- governmental organizations 
and patient associations have identified the most 
efficient route to market for health products. Formal 
network of health professionals help in providing 
feedback and data about health innovation (2) such as 
new drugs in oncology. Cancer is a priority for health 
systems around the world because of three main 
factors: a) the higher incidence, growing and aging 
populations; b) the impact of patients and caregivers 
productivity loss; c) and due to rising treatment costs 
(3).  
A management model integrating budget restrictions, 
ethics, national and international law, society, 
pharmaceutical industry, policymakers, clinicians and 
patients is lacking. We need a new balance of values  
 
 
and new ways of thinking and acting that must 
transcend national and institutional boundaries (4, 5). 
Therefore, the Portuguese paradigm was chosen for 
two reasons: it has a national health service without 
charges for patient in oncology and it has a well-
known European economic crisis with an ageing 
population. Our aim was to stablish the impact of 
crisis in the approval process of reimbursement of 
new drugs for oncology in Portugal accordingly with 
the different stakeholders and, based on that, to 
stablish strategic decisions to minimize the problems.   
 
II. METHODOLOGY 
 
In 29 semi-structured interviews, 27 were tape 
recorded and transcribed to word between November 
2013 and August 2014 (table 1). The ones made in 
Portuguese were translated to English. The interviews 
had an average duration of 35 minutes of recorded 
text (minimum 15 minutes and maximum 85 
minutes).  
 
International Journal of Management and Applied Science, ISSN: 2394-7926 Volume-1, Issue-9,     Special Issue Oct.-2015 
Impact Of The Economic Crisis In The Approval Of New Oncological Drugs – The Portuguese Paradigm 
 
16 
Table 1 – Interviews to the different stakeholders in 
the process of decision for new drugs in oncology 
 
 
A purposive sampling technique was applied to target 
the different stakeholders. The macro, meso and 
micro levels of health care are based on the WHO-
definition (6).  The macro level comprises the health 
system at a central level such as the regulatory 
agencies and government. The meso level comprises 
the health system at both the local and the 
organizational level, such as APIFARMA (Portuguese 
Association of Pharmaceutical Industry), 
INFARMED (National Authority of Drugs and other 
Health Products), hospitals and pharmaceuticals. The 
micro level includes the civil society and oncologists. 
Inclusion of the three groups was considered crucial 
to obtain individuals’ perceptions, and information on 
interactions and on organizational levels of cancer 
care practices. Stakeholders were identified through 
informal and formal networking.  
At least one representative of each group was 
interviewed and the researchers tried to choose 
interviewees with cumulative functions or that have 
already been in other functions besides the ones they 
have at the moment of the study. If invited 
stakeholders were unavailable or refused to be 
interviewed, another person, with a similar profile, 
were invited in a second wave of invitations. There 
were open (i.e. “What can be change?”) and closed 
questions (i.e. like NICE?”). The majority were open 
questions since we did not want that the different 
stakeholders to be limited.  
The main questions were the following: 1) what are 
the main problems in the process of reimbursement of 
the new drugs in the context of European crisis? 2) 
what measures/actions should be or are been taken to 
reduce the costs of new medicines?  
Semantic associations through co-occurrence analysis 
Tropes® software was used as support for content 
analysis and an external validation was made.  
Table 2 - Dictionary of categories. The category 
system used was obtained with the support of the 
Software Tropes® Zoom V7, the English version 
(Cyberlex, 2003; Ferreira, 2008; Moltmann, 2004) 
and English V8.4 
1NOCs – restricted clinical practice guidelines defined 
by Portuguese experts for the different diseases in 
oncology 
2ARS - Regional Administration of Health 
 
 
III. RESULTS 
 
There are "major dynamics that contribute to rising 
health care costs" that are aging, scientific and 
technological advancement and the development of 
practices defensive medicine. The advancement of 
scientific and technological knowledge with the 
discovering of new therapies is extremely expensive 
and creates difficulties to the implementation of 
innovation…” (economist, political decision-maker). 
Portugal has adopted a "policy of controlling costs 
through prices" (APIFARMA decision maker) where 
"basically 49% of the adjustment was done around the 
new drugs..." This administrative policy is reflected in 
two levels "lower prices and reduced access" 
(APIFARMA decision maker). The "exponential 
increase in the cost of drugs is a problem identified 
worldwide" although Portugal is the paradigm of a 
European crisis with lack of money "(INFARMED 
decision maker). However, in the last two years, 
Portugal was "among the three lower European 
countries in terms of per capita public expenditure per 
patient "(APIFARMA decision maker). 
The "pharmaceutical industry through APIFARMA" 
signed an agreement with the government, the 
ministry of health in order to control spending. They 
established a ceiling and all the value that exceeds a 
certain value is returned by pharmaceutical companies 
directly to hospitals in credit notes" (pharmaceutical 
decision maker).  
It is important to "distinguish what are those 
molecules that effectively bring added value, 
therapeutic benefit and quality of life for patients 
from those molecules that are mere novelties" 
(pharmaceutical decision maker). 
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There is an "excessive delay in the approval of new 
drugs, serious limitations and a lack of equity at a 
nationally level." (pharmaceutical decision maker). 
The lack of equity is consensual in our study. It is still 
referred the need for greater transparency in the 
decision-making process.” (sociologist; WHO). The 
funding system in Portugal is a system of the most 
ancient in terms of substantiating a drug-economic 
evaluation. (APIFARMA decision maker). It is 
important demonstrate the added therapeutic value of 
the new oncological drugs and risk sharing 
mechanisms and to investigate the safety and efficacy 
of drugs after its approval (APIFARMA decision 
maker). The "risk-sharing models" has been 
advocated either by policy makers or by decision 
makers in the pharmaceutical industry and is already 
being implemented in Portugal with SINATS 
(hospital decision maker) will be an option and a way 
to cut costs at a public level. In fact, considering the 
rising costs in oncology, the government tries to block 
the access to innovation" (pharmaceutical decision 
maker) and "the pressures are such that the physicians 
often do not use the product ... "(pharmaceutical 
maker). Policy makers claim to have "limited 
resources" (political decision maker). In addition, 
hospitals have "a calculated budget in a certain way” 
and, with the advent of new drugs such as those for 
hepatitis C, “suddenly has to spend another 500 
million or 500,000 or half a million without knowing 
how.” (political decision maker; oncologist).  
Funding is one of the most complex issues and should 
follow the patient as several stakeholders mentioned 
something that is not currently done.  
Clinical trials are a way of getting decrease the 
economic impact of drugs and a way of getting to 
provide treatment to patients spending less and I think 
this is a way to make it more accessible innovation, a 
way that is correct because it also brings additional 
information" (head director of an oncology service). 
Portugal is a “country of reference for many countries 
in Europe" (pharmaceutical decision maker) and 
access difficulties to new drugs have to do with the 
phenomena of parallel exports of drugs to other 
countries" (APIFARMA decision maker).  
Patients´ associations try to defend patients and 
citizens interests so, “they must have interconnection 
with the processes of health” and be more active in 
the decision processes (civil society member).  
Portugal is “not prepared to deal with the huge 
increase of innovation" and some measures are being 
implemented such as the creation of SINATS which is 
a system of health technological evaluation that are 
proposed to be implemented during 2015 and 2016 by 
INFARMED (Hospital decision maker and political 
decision maker).  
Innovation and technological development, costs, 
hospitals with patients and diseases as well as prices, 
particularly of new drugs, are the main factors that 
will influence the health and survival. Consequently 
the state of health of the citizens will influence not 
only the system and cost, but also hospitals, the intake 
of drugs, treatments, communication and business 
(chart 2). 
 
Chart 2 - Factors that influence health, life and 
casualty and its consequences with the respective 
frequency of appearing in the different interviews. 
 
 
DISCUSSION AND CONCLUSION 
 
In our study, it is possible to identify two main 
problems of oncology in Portugal which can are also 
present in other European countries namely, the cost 
of new oncological drugs and the scientific 
development with a huge increase of innovation (7, 
8).  
As confirmed in our study, the three major dynamics 
contributing to the rising costs in health are the 
increasing demand of an ever-expanding and ageing 
population (9, 10, 11), technological breakthrough 
(12) and scientific innovation and the development of 
defensive medicine (13, 14). 
The growing aging of the Portuguese population until 
2050 put increasing pressure on public finances by 
increased expenditure on pensions, elderly care and 
also in health (15, 16). 
Although equity of access to health care is a central 
objective of many health care systems, this is not 
always possible because socio-economic constraints 
(17, 18). In Portugal there is a very serious problem of 
inequality and economic constrains which are leading 
to changes in the process of reimbursement with the 
formation of the National Commission of Pharmacy, 
creation of high differentiation centers and the 
implementation of SINATS (19, 20). SINATS is an 
open model, with active participation of all 
stakeholders which aim the maximization of gains in 
health and quality of life, contribute to the 
sustainability of the National Health Service, ensuring 
the efficient use of public health resources, monitor 
the use and effectiveness of technologies, reducing 
waste and inefficiencies, promote and reward the 
development of relevant innovation (21). 
This new model aims to assess other aspects of the 
value of technology in addition to the added value and 
economic value and will do the evaluation after 
market introduction and it is the most relevant change 
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in the process of reimbursement (22). The question is 
if this model will allow the alignment between 
approval and introduction of new drugs with 
simplification of the process.  The fear of many 
clinicians and society is that the measures that seem 
beneficial "ad initium" may be too restrictive and 
prevent the prescription of drugs already approved 
and marketed in Europe for its clinical benefit (23).  
Health decisions that allow the reduction of costs 
cannot be ethically responsible (24). It is important to 
implement corporate social responsibility (CSR) 
which "is not only doing the right but also make 
things better" (25). In health organizations there is 
evidence that, for the implementation of 
organizational changes, the agents have to overcome 
the resistance of the other members of the 
organization for the adoption of new practices (26). 
So, whereas the decision for the approval of new 
cancer therapies should be based on ethics, integrating 
civil society and consider the patient (the main 
"stakeholder") (27), it is important to implement 
changes that integrate CSR in Portuguese model 
(even if there is resistance on the need to change the 
organizational culture). However, without a structural 
reform in the National Health Service it will be 
difficult to maintain a high quality level in the area of 
oncology without compromising the economic 
sustainability. Moreover, a change in the system of 
evaluation for innovative drugs is important for all 
European countries in order to maintain sustainability. 
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